• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic delivery >Challenges and opportunities in the delivery of cancer therapeutics
【24h】

Challenges and opportunities in the delivery of cancer therapeutics

机译：癌症治疗药物的挑战和机遇

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The idea that cancer is not one but many diseases has completely changed the oncology landscape and promoted the development of personalized cancer therapy. Based on a better understanding of the mechanisms of cancer cell proliferation and tumor growth, novel therapies have emerged to address unmet medical needs and effectively treat pre-identified, responsive patients. These novel therapies require specific drug-delivery strategies that depend on the type and location of cancer, as well as the type of drugs administered, that is, a small molecule, a peptide, a therapeutic protein or a monoclonal antibody. Systemic cancer drugs are administered through three major routes that show different challenges with regard to delivery: these are oral administration, intravenous infusion and subcutaneous injection. This review presents and discusses the challenges and opportunities of the drug-delivery systems for each of these administration routes. It will be shown that, for the good of the patients, every time a drug-delivery system is used to administer anticancer drugs, the patients get a major benefit from that specific system: either improved efficacy, a better tolerability and toxicity profile, or even a combination of both effects.
机译：癌症不是一种疾病而是多种疾病的观念已经完全改变了肿瘤学领域，并促进了个性化癌症治疗的发展。基于对癌细胞增殖和肿瘤生长机制的更好理解，出现了新的疗法以解决未满足的医疗需求并有效治疗预先确定的反应性患者。这些新颖的疗法需要特定的药物递送策略，该策略取决于癌症的类型和位置以及所用药物的类型，即小分子，肽，治疗性蛋白质或单克隆抗体。全身性抗癌药物通过三种主要途径给药，这些途径在给药方面表现出不同的挑战：口服给药，静脉输注和皮下注射。这篇综述提出并讨论了每种给药途径的药物输送系统所面临的挑战和机遇。结果表明，从患者的利益出发，每次使用药物递送系统来施用抗癌药物，患者都会从该特定系统中受益匪浅：提高疗效，更好的耐受性和毒性，或者甚至是两种效果的组合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号